FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers
Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.
Read More
Understanding the Role of Zanubrutinib for the Treatment of CLL
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
Listen
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.
Exciting Activity in Chronic Lymphocytic Leukemia
In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.
Advancements in Follicular Lymphoma Treatment With Targeted Therapies
At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.
Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine
Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.
